Skip to main content
Erschienen in: Infection 3/2013

01.06.2013 | Clinical and Epidemiological Study

A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade

verfasst von: A. M. Tortorano, A. Prigitano, C. Lazzarini, M. Passera, M. L. Deiana, S. Cavinato, C. De Luca, A. Grancini, G. Lo Cascio, C. Ossi, E. Sala, M. T. Montagna

Erschienen in: Infection | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to assess the epidemiology of candidemia and antifungal susceptibility profiles of Candida isolates in Italy through a prospective surveillance study and to evaluate changes compared to a previous survey performed in one Italian region (Lombardy) in 1997–1999.

Methods

A prospective laboratory-based surveillance of candidemia was performed in Italy from January to December 2009. For each case a questionnaire was filled in, and the first isolate was collected and tested for in vitro antifungal susceptibility.

Results

During our 12-month survey, 467 episodes of candidemia were reported from 34 centres (30 located in Lombardy) and 464 isolates collected. Candida albicans was the predominant species (overall incidence 50.4 %), but the proportion varied considerably from 52.1 % in Lombardy hospitals to 45.2 % hospitals located outside this region. The second most frequent species was C. glabrata in Lombardy and C. parapsilosis in other regions. Comparison of the 1997–1999 and 2009 data on episodes of candidemia in Lombardy revealed a threefold increase in incidence (from 0.38 to 1.19 per 1,000 admissions), aging of infected patients, decline in crude mortality (from 35 to 27.1 %) and an increased proportion of C. glabrata etiology (from 12.8 to 20.3 %). Susceptibility testing confirmed the broad activity of amphotericin B and echinocandins. Decreased susceptibility to fluconazole was found in 24.9 % of the tested isolates.

Conclusions

The results of this latest survey confirm the high rate of candidemia in Italy and show changes in some of the epidemiological tracts, such as aging of infected patients, increased proportion of C. glabrata infections, increased diagnosis in medical wards, and improvement in patients’ survival.
Literatur
2.
Zurück zum Zitat Ahlquist Cleveland A, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller T. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55:1352–61.CrossRef Ahlquist Cleveland A, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller T. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55:1352–61.CrossRef
3.
Zurück zum Zitat Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Krogh Johansen H, Kjældgaard P, Knudsen JD, Kristensen L, Møller J, Nielsen L, Rosenvinge FS, Røder B, Schønheyder HC, Thomsen MK, Truberg K. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011;49:325–34. doi:10.1128/JCM.01811-10.PubMedCrossRef Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Krogh Johansen H, Kjældgaard P, Knudsen JD, Kristensen L, Møller J, Nielsen L, Rosenvinge FS, Røder B, Schønheyder HC, Thomsen MK, Truberg K. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011;49:325–34. doi:10.​1128/​JCM.​01811-10.PubMedCrossRef
4.
Zurück zum Zitat Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14:e954–66. doi:10.1016/j.ijid.2010.04.006.PubMedCrossRef Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14:e954–66. doi:10.​1016/​j.​ijid.​2010.​04.​006.PubMedCrossRef
5.
Zurück zum Zitat Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, Perin S, Bonaccorso C, Cavanna C, Raballo A, Grossi A. European Confederation of Medical Mycology (ECMM) prospective survey ofcandidemia: report from one Italian region. J Hosp Infect. 2002;51:297–304. doi:10.1053/jhin.2002.1261.PubMedCrossRef Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, Perin S, Bonaccorso C, Cavanna C, Raballo A, Grossi A. European Confederation of Medical Mycology (ECMM) prospective survey ofcandidemia: report from one Italian region. J Hosp Infect. 2002;51:297–304. doi:10.​1053/​jhin.​2002.​1261.PubMedCrossRef
6.
Zurück zum Zitat Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Donnelly JP, Dromer F, Fegeler W, Lass-Florl C, Moore CB, Richardson M, Sandven P, Velegraki A, Verweij PE. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398–405. doi:10.1111/j.1469-0691.2007.01935.x.CrossRef Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Donnelly JP, Dromer F, Fegeler W, Lass-Florl C, Moore CB, Richardson M, Sandven P, Velegraki A, Verweij PE. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398–405. doi:10.​1111/​j.​1469-0691.​2007.​01935.​x.CrossRef
8.
Zurück zum Zitat Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehand D. Wild-type MIC distributions, epidemiological cut-off values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:180–95. doi:10.1016/j.drup.2010.09.002.PubMedCrossRef Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehand D. Wild-type MIC distributions, epidemiological cut-off values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:180–95. doi:10.​1016/​j.​drup.​2010.​09.​002.PubMedCrossRef
9.
Zurück zum Zitat Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14:164–76. doi:10.1016/j.drup.2011.01.004.PubMedCrossRef Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14:164–76. doi:10.​1016/​j.​drup.​2011.​01.​004.PubMedCrossRef
10.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Document M27–A3. Wayne: Clinical and Laboratory Standards Institute; 2008. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Document M27–A3. Wayne: Clinical and Laboratory Standards Institute; 2008.
15.
Zurück zum Zitat Arendrup MC, Fuursted K, Gahrn-Hansen B, Schønheyder HC, Knudsen JD, Jensen IM, Bruun B, Christensen JJ, Johansen HK. Semi-national surveillance of fungaemia in Denmark 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microb Infect. 2008;14:487–94. doi:10.1111/j.1469-0691.2008.01954.x.CrossRef Arendrup MC, Fuursted K, Gahrn-Hansen B, Schønheyder HC, Knudsen JD, Jensen IM, Bruun B, Christensen JJ, Johansen HK. Semi-national surveillance of fungaemia in Denmark 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microb Infect. 2008;14:487–94. doi:10.​1111/​j.​1469-0691.​2008.​01954.​x.CrossRef
16.
Zurück zum Zitat Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–8. doi:10.1128/AAC.01128-10.PubMedCrossRef Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–8. doi:10.​1128/​AAC.​01128-10.PubMedCrossRef
18.
Zurück zum Zitat Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Täuber MG, Pittet D, Fungal Infection Network of Switzerland (FUNGINOS). Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004;38:311–20. doi:10.1086/380637.PubMedCrossRef Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Täuber MG, Pittet D, Fungal Infection Network of Switzerland (FUNGINOS). Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004;38:311–20. doi:10.​1086/​380637.PubMedCrossRef
19.
Zurück zum Zitat von Borg-Zepelin M, Kunz L, Ruchel R, Reichard U, Weig M, Groß U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother. 2007;60:424–8. doi:10.1093/jac/dkm145.CrossRef von Borg-Zepelin M, Kunz L, Ruchel R, Reichard U, Weig M, Groß U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother. 2007;60:424–8. doi:10.​1093/​jac/​dkm145.CrossRef
21.
Zurück zum Zitat Cisterna R, Ezpeleta G, Telleria O, Guinea J, Regueiro B, Garcia-Rodríguez J, Esperalba J, The Spanish Candidemia Surveillance Group. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clinical Microbiol. 2010;48:4200–6. doi:10.1128/JCM.00920-10.CrossRef Cisterna R, Ezpeleta G, Telleria O, Guinea J, Regueiro B, Garcia-Rodríguez J, Esperalba J, The Spanish Candidemia Surveillance Group. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clinical Microbiol. 2010;48:4200–6. doi:10.​1128/​JCM.​00920-10.CrossRef
22.
Zurück zum Zitat Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE. 2011;6:e24198. doi:10.1371/journal.pone.0024198.PubMedCrossRef Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE. 2011;6:e24198. doi:10.​1371/​journal.​pone.​0024198.PubMedCrossRef
24.
Zurück zum Zitat Prigitano A, Dho G, Lazzarini C, Ossi C, Cavanna C, Tortorano AM. Biofilm production by Candida isolates from a survey of invasive fungal infections in Italian intensive care units. J Chemother. 2012;24:61–3.PubMed Prigitano A, Dho G, Lazzarini C, Ossi C, Cavanna C, Tortorano AM. Biofilm production by Candida isolates from a survey of invasive fungal infections in Italian intensive care units. J Chemother. 2012;24:61–3.PubMed
Metadaten
Titel
A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade
verfasst von
A. M. Tortorano
A. Prigitano
C. Lazzarini
M. Passera
M. L. Deiana
S. Cavinato
C. De Luca
A. Grancini
G. Lo Cascio
C. Ossi
E. Sala
M. T. Montagna
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 3/2013
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0455-6

Weitere Artikel der Ausgabe 3/2013

Infection 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.